Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 54.2% in March

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 13,325 shares, an increase of 54.2% from the March 15th total of 8,642 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 18,013 shares, the short-interest ratio is currently 0.7 days.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Stock Up 10.7%

INDP traded up $0.22 during trading on Tuesday, reaching $2.28. The stock had a trading volume of 189,512 shares, compared to its average volume of 66,469. The firm has a market capitalization of $5.11 million, a price-to-earnings ratio of -0.09 and a beta of 0.97. Indaptus Therapeutics has a 1-year low of $1.51 and a 1-year high of $19.91. The stock has a 50 day moving average of $1.83 and a two-hundred day moving average of $2.47.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Tuesday, March 17th. The company reported ($3.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.36) by $1.26. On average, research analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.